Veterinary clinical pathologists in the biopharmaceutical industry

Veterinary Clinical Pathology

Volumn 37, Issue 2, 2008, Pages 146-158

  Schultze, A Eric ^a   Bounous, Denise I ^b   Bolliger, Anne Provencher ^c  

^a ELI LILLY AND COMPANY   (United States)

^b BRISTOL MYERS SQUIBB   (United States)

^c NOVARTIS PHARMA AG   (Switzerland)

Author keywords

Biopharmaceutical industry; Career options; Drug development; Safety assessment; Toxicology; Veterinary clinical pathologist

Indexed keywords

BIOLOGICAL MARKER; NEW DRUG;

ARTICLE; CLINICAL TRIAL; DRUG DESIGN; DRUG INDUSTRY; MANPOWER; PATHOLOGY; TIME; VETERINARY MEDICINE;

BIOLOGICAL MARKERS; CLINICAL TRIALS AS TOPIC; DRUG DESIGN; DRUG INDUSTRY; DRUGS, INVESTIGATIONAL; PATHOLOGY, CLINICAL; TIME FACTORS; VETERINARIANS;

EID: 47649124350     PISSN: 02756382     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1939-165X.2008.00041.x     Document Type: Article

References (17)

1. Veterinary Pathologist Survey: Final Report. American College of Veterinary Pathologists, July 2002. Available at: http://www.acvp.org/news/. Accessed July 23, 2007.
2. Membership Directory of the American College of Veterinary Pathology, 1987, 1997, 2002, 2007.
3. Membership Directory for the Society of Toxicologic Pathology. Available at: http://www.toxpath.org/. Accessed August 8, 2007.
4. International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use. ICH Harmonised Tripartite Guideline M3(M). Maintenance of the ICH guideline on nonclinical safety studies for the conduct of human clinical trials for pharmaceuticals, 2000:1-7.
5. Schultze AE, Sullivan JM. Screening a novel class of anticoagulants for multi-organ toxicity using Fischer 344 rats: involvement of clinical and anatomic pathologists in the early drug development process. Vet Clin Pathol. 2007;36:123-136.
6. What Do Veterinary Clinical Pathologists Do? American Society for Veterinary Clinical Pathology. Available at: http://www.asvcp.org/WhatIsaCP.ppt. Accessed December 20, 2007.
7. Leader RW. Toxicologic pathology: an introduction. In: Haschek WM, Rousseaux CG, eds. Handbook of Toxicologic Pathology. San Diego, C A: Academic Press Inc; 1991:1-8.
8. Vahle JL, Tashijan Jr AH. Drug discovery and preclinical development. In: Golan DE, Tashjian Jr AH, Armstrong EJ, Armstrong AW, eds. Principles of Pharmacology - The Pathophysiologic Basis of Drug Therapy. 2nd ed. Philadelphia, PA: Lippincott Williams and Wilkins; 2008:851-873.
9. Dorato MA, McMillian CL, Vodicnik MJ. The toxicologie assessment of pharmaceutical and biotechnology products. In: Hayes AW, ed. Principles and Methods of Toxicology. 5th ed. Boca Raton, FL: CRC Press/Taylor and Francis; 2008:325-367.
10. DiMasi JA, Hansen RW, Grabowski HG. The price of innovation: new estimates of drug development costs. J Health Econom. 2003;22:151-185.
11. Pharmaceutical Research and Manufacturers of America, Pharmaceutical Industry Profile 2007, Washington, DC, PhRMA, March 2007. Available at: http://www.phrma.org/proflles_&_reports/. Accessed October 30, 2007.
12. Boone L, Meyer D, Cusick P, et al. Selection and interpretation of clinical pathology indicators of hepatic injury in preclinical studies. Vet Clin Pathol. 2005;34:182-188.
13. Stromberg P. Why you should consider becoming a veterinary pathologist. Compend Contin Educ Pract Vet. 2007;29:516-517.
14. Biomarkers Definitions Working Group. Biomarkers and surrogate endpoints: preferred definitions and conceptual framework. 2001;69:89-95.
15. Boverhof DR, Zacharewski TR. Toxicogenomics in risk assessment: applications and needs. Toxicol Sci. 2006;89:352-360.
16. Scares O, Fisler R. Biomarker technology roundup: from discovery to clinical applications, a broad set of tools is required to translate from the lab to the clinic. BioTechniques. 2005;38:S30-S32.
17. Food and Drug Administration Compliance Program Guidance Manual. Available at: http://www.fda.gov/ora/compliance_ref/bimo/7348_808/48-808.pdf. Accessed October 30, 2007.